Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis

Journal of Neurology

Volumn 253, Issue 3, 2006, Pages 287-293

  Tomassini, Valentina ^d   Paolillo, Andrea ^d   Russo, Pierluigi ^a   Giugni, Elisabetta ^d   Prosperini, Luca ^d   Gasperini, Claudio ^b   Antonelli, Guido ^a   Bastianello, Stefano ^c   Pozzilli, Carlo ^d  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Interferon beta; MRI; Neutralizing antibodies; Predictors

Indexed keywords

BETA1A INTERFERON; GADOLINIUM; INTERFERON BETA SERINE; NEUTRALIZING ANTIBODY;

ADULT; ARTICLE; CLINICAL EXAMINATION; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMOGRAPHY; DISABILITY; DISEASE COURSE; DISEASE MARKER; EVALUATION; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION; PRIORITY JOURNAL; RECURRENCE RISK; RISK FACTOR; SEX DIFFERENCE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; CONFIDENCE INTERVALS; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; HUMANS; INTERFERON-BETA; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NEUROLOGIC EXAMINATION; ODDS RATIO; TREATMENT OUTCOME;

EID: 33644964929     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-005-0979-5     Document Type: Article

References (48)

1. Confavreux C, Aimard G, Devic M (1980) Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain 103:281-300
2. Confavreux C, Vukusic S, Adeleine P (2003) Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 126:770-782
3. Weinshenker BG, Bass B, Rice GP, et al. (1989) The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 112:133-146
4. Weinshenker BG, Bass B, Rice GP, et al. (1989) The natural history of multiple sclerosis: a geographically based study. II. Predictive value of the early clinical course. Brain 112:1419-1428
5. Runmarker B, Andersen O (1993) Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 116:117-134
6. Trojano M, Avolio C, Manzari C, et al. (1995) Multivariate analysis of predictive factors of multiple sclerosis course with a validated method to assess clinical events. J Neurol Neurosurg Psychiatry 58:300-306
7. Kantarci O, Siva A, Eraksoy M, et al. (1998) Survival and predictors of disability in Turkish MS patients. Turkish Multiple Sclerosis Study Group (TUMSSG). Neurology 51:765-772
8. Filippi M, Horsfield MA, Morrissey SP, et al. (1994) Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology 44:635-641
9. O'Riordan JI, Thompson AJ, Kingsley DP, et al. (1998) The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain 121:495-503
10. Brex PA, Ciccarelli O, O'Riordan JI, Sailer M, Thompson AJ, Miller DH (2002) A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 346:158-164
11. Barkhof F, Filippi M, Miller DH, et al. (1997) Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 120:2059-2069
12. Kappos L, Moeri D, Radue EW, et al. (1999) Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group. Lancet 353:964-969
13. CHAMPS Study Group (2002) MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group. Neurology 59:998-1005
14. The IFN beta Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology 43:655-661
15. Jacobs LD, Cookfair DL, Rudick RA, et al. (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39:285-294
16. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis (1998) PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 352:1498-1504
17. Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444-1452
18. Koudriavtseva T, Pozzilli C, Fiorelli M, et al. (1998) Determinants of Gd-enhanced MRI response to IFN-beta-1a treatment in relapsing-remitting multiple sclerosis. Mult Scler 4:403-407
19. Waubant E, Vukusic S, Gignoux L, et al. (2003) Clinical characteristics of responders to interferon therapy for relapsing MS. Neurology 61:184-189
20. Vermersch P, de Seze J, Stojkovic T; G-SEP (Groupe Septentrional d'Etudes et de Recherches sur la SEP) (2002) Interferon beta 1a (Avonex) treatment in multiple sclerosis: similarity of effect on progression of disability in patients with mild and moderate disability. J Neurol 249:184-187
21. The IFNB Multiple Sclerosis study group and the University of British Columbia MS/MRI analysis group (1996) Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 47:889-894
22. Soelberg Sorensen P, Ross C, Clemmesen KM, et al. (2003) Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 362:1184-1191
23. Pozzilli C, Bastianello S, Koudriavtseva T, et al. (1996) Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short term study in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 61:251-258
24. Paolillo A, Pozzilli C, Giugni E, et al. (2002) A 6-year clinical and MRI follow-up study of patients with relapsing-remitting multiple sclerosis treated with interferon-beta. Eur J Neurol 9:645-655
25. Bellomi F, Scagnolari C, Tomassini V, et al. (2003) Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years. J Neurol Sci 215:3-8
26. WHO Expert Committee on Biological Standardisation (1985) Thirty-fifth report. WHO technical report series 725. Geneva: World Health Organization
27. Kawade Y (1986) Quantitation of neutralization of interferon by antibody. Methods Enzymol 119:558-573
28. Grossberg SE, Kawade Y, Kohase M, Klein JP (2001) The neutralization of interferon by antibody. II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit. J Interferon Cytokine Res 21:743-755
29. Grimaud J, Lai M, Thorpe J, et al. (1996) Quantification of MRI lesion load in multiple sclerosis: a comparison of three computer-assisted techniques. Magn Reson Imaging 14: 495-505
30. Miller DH, Grossman RI, Reingold SC, McFarland HF (1998) The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Brain 121:3-24
31. Rio J, Nos C, Tintore M, et al. (2002) Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon beta: implications for clinical trials. Ann Neurol 52:400-406
32. Rudick RA, Fisher E, Lee JC, Duda JT, Simon J (2000) Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1a. Mult Scler 6:365-372
33. McFarland HF, Barkhof F, Antel J, Miller DH (2002) The role of MRI as surrogate outcome measure in multiple sclerosis. Mult Scler 8:40-51
34. Van Walderveen MA, Kamphorst W, Scheltens P, et al. (1998) Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology 50:1282-1288
35. Van Waesberghe JH, Kamphorst W, De Groot CJ, et al. (1999) Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol 46:747-754
36. Truyen L, Van Waesberghe JH, Van Walderveen MA, et al. (1996) Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis. Neurology 47:1469-1476
37. Simon JH, Lull J, Jacobs LD, et al. (2000) A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon beta-1a. Multiple Sclerosis Collaborative (Research Group). Neurology 55:185-192
38. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group (2001) Randomized controlled trial of interferon beta-1a in secondary progressive MS: clinical results. Neurology 56:1496-1504
39. Li DK, Zhao GJ, Paty DW, University of British Columbia MS/MRI Analysis Research Group, The SPECTRIMS Study Group (2001) Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results. Neurology 56:1505-1513
40. De Cicco Nardone F, Rossiello F, Iacopino F, et al. (1996) Effects of interferon-beta on steroid receptors, prostaglandins and enzymatic activities in human endometrial cancer. Anticancer Res 16:161-169
41. Barak V, Kalickman I, Nisman B, et al. (1998) Changes in cytokine production of breast cancer patients treated with interferons. Cytokine 10:977-983
42. van Walderveen MA, Lycklama A, Nijeholt GJ, et al. (2001) Hypointense lesions on T1-weighted spin-echo magnetic resonance imaging: relation to clinical characteristics in subgroups of patients with multiple sclerosis. Arch Neurol 58(1):76-81
43. Pozzilli C, Tomassini V, Marinelli F, et al. (2003) "Gender gap" in multiple sclerosis: magnetic resonance imaging evidence. Eur J Neurol 10:95-97
44. Perini P, Calabrese M, Biasi G, Gallo P (2004) The clinical impact of interferon beta antibodies in relapsing-remitting MS. J Neurol 251:305-309
45. Malucchi S, Sala A, Gilli F, et al. (2004) Neutralizing antibodies reduce the efficacy of beta IFN during treatment of multiple sclerosis. Neurology 62:2031-2037
46. Polman C, Kappos L, White R, et al. (2003) European Study Group in Interferon Beta-1b in Secondary Progressive MS. Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b. Neurology 60:37-43
47. Molyneux PD, Filippi M, Barkhof F, et al. (1998) Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis. Ann Neurol 43:332-339
48. Rudick RA, Lee JC, Simon J, et al. (2004) Defining interferon beta response status in multiple sclerosis patients. Ann Neurol 56:548-555